School of Psychology, University of Queensland, Brisbane, Australia.
Behav Cogn Psychother. 2010 Jul;38(4):479-83. doi: 10.1017/S1352465810000093. Epub 2010 Mar 26.
The aim was to investigate whether high catecholamine (CA) excreters would respond less well to a group cognitive behaviour therapy (CBT) treatment for depression than others.
A sample of 70 adults with depression symptoms participated in a 12-week course of group CBT. Participants' 24 hour urinary catecholamine levels at pre-therapy and post-therapy were used to classify them as High (N = 10); Low (N = 33) or Mixed (N = 27) according to a cut-off one standard deviation above a published mean for healthy adults. Beck Depression Inventory (BDI) and cognitions questionnaire (Automatic Thoughts Questionnaire; Beck Hopelessness Scale and Dysfunctional Attitudes Scale) were used.
Repeated measures ANOVA analyses showed an equal rate of mood improvement in all three groups over the course of CBT, despite the fact that the High excreters were on average more depressed throughout the study. Changes in depression symptoms were mirrored by improvements in cognitive measures in the three catecholamine groups.
This study indicates that adults showing a biological marker of depression (elevated catecholamine levels) are equally able to benefit from CBT treatment as adults without this marker.
本研究旨在探讨高儿茶酚胺(CA)排泄者对团体认知行为疗法(CBT)治疗抑郁症的反应是否不如其他患者。
本研究共纳入 70 名有抑郁症状的成年人,他们参加了为期 12 周的团体 CBT 治疗。根据已发表的健康成年人平均水平的一个标准差以上的截点值,将参与者治疗前后 24 小时尿儿茶酚胺水平分类为高(N=10)、低(N=33)或混合(N=27)。采用贝克抑郁量表(BDI)和认知问卷(自动思维问卷、贝克绝望量表和功能失调态度量表)进行评估。
重复测量方差分析显示,尽管高排泄者在整个研究过程中平均抑郁程度更高,但在 CBT 过程中,三组患者的情绪改善率相同。在三个儿茶酚胺组中,抑郁症状的变化与认知测量的改善相匹配。
本研究表明,表现出抑郁生物标志物(升高的儿茶酚胺水平)的成年人与没有该标志物的成年人一样,能够从 CBT 治疗中同等获益。